Cartesian Therapeutics (RNAC) Operating Leases (2018 - 2026)
Cartesian Therapeutics (RNAC) posted quarterly Operating Leases of $7.7 million for Q1 2026, down 45.48% year-over-year from $14.1 million in Q1 2025, and down 10.04% quarter-over-quarter from $8.5 million in Q4 2025.
Cartesian Therapeutics (RNAC) Operating Leases (2018 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has reported Operating Leases for 9 consecutive years, with $7.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Leases fell 45.48% year-over-year to $7.7 million; the TTM figure through Mar 2026 stood at $7.7 million (down 45.48% YoY), while the FY2025 annual figure was $8.5 million, down 23.43% from the prior year.
- Operating Leases fell to $7.7 million in Q1 2026 per RNAC's latest filing, from $8.5 million in the prior quarter.
- Across five years, Operating Leases topped out at $14.1 million in Q1 2025 and bottomed at $3.2 million in Q4 2022.
- Historically, Operating Leases has averaged $9.7 million across 5 years, with a median of $9.2 million in 2023.
- Annual changes were most pronounced in 2022 — Operating Leases sank 62.78% — and 2023, when it soared 174.66%.
- Cartesian Therapeutics' Operating Leases stood at $3.2 million in 2022, then jumped by 174.66% to $8.8 million in 2023, then rose by 26.67% to $11.1 million in 2024, then decreased by 23.43% to $8.5 million in 2025, then slipped by 10.04% to $7.7 million in 2026.
- Business Quant data shows RNAC's Operating Leases at $7.7 million in Q1 2026, $8.5 million in Q4 2025, and $8.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Cartesian Therapeutics | 265.54 Mn | 265.54 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.00 Mn |
| Mar 31, 2026 | 7.67 Mn |
| Dec 31, 2025 | 8.53 Mn |
| Sep 30, 2025 | 8.73 Mn |
| Jun 30, 2025 | 9.56 Mn |
| Mar 31, 2025 | 14.07 Mn |
| Dec 31, 2024 | 11.13 Mn |
| Sep 30, 2024 | 11.88 Mn |
| Jun 30, 2024 | 12.34 Mn |
| Mar 31, 2024 | 8.23 Mn |
| Dec 31, 2023 | 8.79 Mn |
| Sep 30, 2023 | 10.48 Mn |
| Jun 30, 2023 | 9.16 Mn |
| Mar 31, 2023 | 11.29 Mn |
| Dec 31, 2022 | 3.20 Mn |
| Sep 30, 2022 | 12.06 Mn |
| Jun 30, 2022 | 9.14 Mn |
| Mar 31, 2022 | 8.32 Mn |
| Dec 31, 2021 | 8.60 Mn |
| Sep 30, 2021 | 8.87 Mn |